%0 Journal Article
%T Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
%A Feldman GJ
%J International Journal of Chronic Obstructive Pulmonary Disease
%D 2013
%I 
%R http://dx.doi.org/10.2147/COPD.S31209
%X oving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol Review (1489) Total Article Views Authors: Feldman GJ Published Date February 2013 Volume 2013:8 Pages 89 - 96 DOI: http://dx.doi.org/10.2147/COPD.S31209 Received: 18 September 2012 Accepted: 26 November 2012 Published: 14 February 2013 Gregory J Feldman S Carolina Pharmaceutical Research, Alliance Biomedical Group International, Spartanburg, SC, USA Abstract: Chronic obstructive pulmonary disease (COPD) is a common disease in the general population and it places a considerable burden on patients, with the disease negatively affecting quality of life. In practice, patients with COPD generally seek medical attention because of symptoms, particularly breathlessness, and the resulting physical limitations, which affect the health-related quality of life (HR-QOL) in patients. The defining feature of COPD is airflow limitation that causes air trapping and increased hyperinflation as the ventilation rate increases during physical effort. Hyperinflation causes or worsens breathlessness as breathing becomes inefficient, with the end result being an avoidance of physical exertion and a cycle of increasing dyspnea caused by inactivity and deconditioning, with deleterious effects on HR-QOL. Current published guidelines for COPD state that the goals of pharmacologic therapy should be to control symptoms, improve health status and exercise tolerance, and reduce the frequency of COPD exacerbations. Effective and sustained bronchodilation has emerged as a key strategy for improving dyspnea and ability to exercise. As there is no cure for COPD, a major goal of treatment and of research into new therapies is to improve HR-QOL in COPD patients. Conclusion: More recently, indacaterol, an inhaled ultra-long-acting ¦Â2-agonist (24-hour action), has been approved in many countries at different doses (between 75 and 300 ¦Ìg once daily) for treatment of patients with stable but symptomatic COPD. The aim of this review was to explore once-daily indacaterol clinical data as related to improvement in HR-QOL in COPD. Indacaterol studies have shown significant improvements in lung function of COPD patients, and these improvements have also translated into clinically meaningful improvements in patient symptoms and HR-QOL.
%K airflow limitation
%K bronchodilation
%K long-acting ¦Â2-agonist
%K COPD
%U https://www.dovepress.com/improving-the-quality-of-life-in-patients-with-chronic-obstructive-pul-peer-reviewed-article-COPD